China Shineway Pharmaceutical Group (2877) Fundamentals 2026 — P/E 5.7x, Revenue Analysis | SniperIQ
China Shineway Pharmaceutical Group (2877) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK$6.2B, trading at HK$8.24 on the HKSE. This SniperIQ fundamentals page covers China Shineway Pharmaceutical Group's valuation (P/E 5.7x, P/B 0.7x), profitability (net margin 30.3%), revenue (¥3.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Shineway Pharmaceutical Group's market cap?
China Shineway Pharmaceutical Group (2877) has a market capitalization of approximately HK$6.2B, trading at HK$8.24 on the HKSE. Market cap moves with the live share price.
What is China Shineway Pharmaceutical Group's P/E ratio?
China Shineway Pharmaceutical Group's trailing twelve-month P/E ratio is 5.7x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Shineway Pharmaceutical Group?
China Shineway Pharmaceutical Group runs a net profit margin of 30.3%, a gross margin of 72.3%, and an operating margin of 21.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Shineway Pharmaceutical Group generate?
China Shineway Pharmaceutical Group reported revenue of ¥3.1B for fiscal year 2025, with net income of ¥950M and earnings per share (EPS) of 1.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Shineway Pharmaceutical Group pay a dividend?
China Shineway Pharmaceutical Group offers a trailing dividend yield of about 7.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China Shineway Pharmaceutical Group financially healthy?
China Shineway Pharmaceutical Group carries a debt-to-equity ratio of 0.04x and a current ratio of 3.71x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Shineway Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Shineway Pharmaceutical Group (2877) the key facts are: market cap HK$6.2B, P/E 5.7x, revenue ¥3.1B, 52-week range 7.21-10.47. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Shineway Pharmaceutical Group's full fundamentals live
Get China Shineway Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.